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ABSTRACT	  
GPx8	   is	   a	   mammalian	   Cys-­‐glutathione	   peroxidase	   of	   the	   endoplasmic	   reticulum	   membrane,	  
involved	   in	  protein	  folding.	   Its	  regulation	   is	  mostly	  unknown.	  We	  addressed	  both,	   functionality	  of	  
two	  hypoxia	   response	  elements	   (HREs)	  within	   the	  promoter,	  GPx8-­‐HRE1	  and	  GPx8-­‐HRE2	  and	   the	  
GPx8	   physiological	   role.	   In	   HeLa	   cells,	   treatment	   with	   HIFα	   stabilizers,	   such	   as	   diethyl	   succinate	  
(DES)	   or	   2-­‐2’–bipyridyl	   (BP)	   induces	   GPx8	   mRNA	   1.5	   fold.	   Luciferase	   activity	   of	   pGL3GPx8wt,	  
containing	  a	  fragment	  of	  the	  GPx8	  promoter	  including	  the	  two	  HREs,	  is	  also	  induced	  by	  DES/BP	  or	  
by	  overexpressing	  either	  individual	  HIFα	  subunit.	  Mutating	  GPx8-­‐HRE1	  within	  pGL3GPx8wt	  resulted	  in	  
a	   significantly	   higher	   inhibition	   of	   luciferase	   activity	   than	   mutating	   GPx8-­‐HRE2.	   EMSA	   analysis	  
showed	   that	  both	  HREs	  exhibit	   enhanced	  binding	   to	  a	  nuclear	  extract	   from	  DES/BP-­‐treated	   cells,	  
with	   stronger	   binding	   by	  GPx8-­‐HRE1.	   In	  DES-­‐treated	   cells	   transfected	  with	   pGL3GPx8wt	   or	  mutants	  
thereof,	  silencing	  of	  HIF2α, 	  but	  not	  HIF1α, 	  abolishes	   luciferase	  activity.	  Thus	  GPx8	   is	  a	  novel	  HIF	  
target	  preferentially	  responding	  to	  HIF2α	  binding	  at	  its	  two	  novel	  functional	  GPx8-­‐HREs,	  with	  GPx8-­‐
HRE1	  playing	   the	  major	   role.	   FGF	   treatment	   increases	  GPx8	  mRNA	  expression	  and	   reporter	   gene	  
experiments	  indicate	  that	  induction	  occurs	  via	  HIF.	  Comparing	  the	  effect	  of	  depleting	  GPx8	  on	  the	  
downstream	  effectors	  of	  FGF	  or	  insulin	  signaling,	  revealed	  that	  absence	  of	  GPx8	  results	  in	  a	  16	  or	  
12	  fold	  increase	  of	  phosphorylated	  ERK	  1/2	  -­‐	  by	  FGF	  or	  insulin	  treatment	  respectively.	  Furthermore,	  
in	  GPx8	  depleted	  cells,	  phosphorylation	  of	  AKT	  by	  insulin	  treatment	  increases	  2.5	  fold.	  We	  suggest	  
that	  induction	  of	  GPx8	  expression	  by	  HIF	  slows	  down	  proliferative	  signaling	  during	  hypoxia	  and/or	  
growth	  stimulation	  through	  receptor	  tyrosine	  kinases.	  
	  
	  
















å	   	  
Introduction	  
	  
In	  excess,	  hydroperoxides	   (ROOH)1	  have	  a	  pro-­‐inflammatory	   role	  and	  are	   toxic	   to	  cells.	  However,	  
when	   produced	   in	   limited	   amounts	   associated	   with	   physiological	   signaling,	   ROOH	   appear	   to	  
modulate	   redox	   sensitive	   processes	   including	   growth,	   differentiation,	   and	   proliferation	   [1-­‐4].	  
Emerging	  knowledge	  suggests	  that	  ROOH	  are	  required	  for	  receptor	  tyrosine	  kinase	  (RTK)	  signaling	  
with	  the	  intriguing	  function	  of	  amplifying	  the	  RTK	  signaling	  cascades	  [1,5].	  	  	  
The	   glutathione	   peroxidase	   (GPx)	   family	   of	   proteins	   encompasses	   distinct	   gene	   products	   that	  
efficiently	  reduce	  ROOH	  into	  corresponding	  alcohols.	  Inverse	  genetic	  studies	  suggest	  that	  they	  are	  
non-­‐redundant	  enzymes,	  despite	  catalyzing	  a	  similar	  reaction	  and	  often	  exhibiting	  an	  overlapping	  
cellular	   distribution	   [6].	   In	   humans,	   the	   family	   of	   glutathione	  peroxidases	   includes	  members	   that	  
may	  contain	  either	  the	  rare	  amino	  acid	  selenocysteine	  (Sec),	  or	  the	  more	  common	  cysteine	  (Cys)	  as	  
the	  redox	  active	  moiety.	  Apart	  from	  that,	  in	  both	  subfamilies	  the	  redox-­‐active	  residue	  is	  included	  in	  
a	  conserved	  catalytic	  tetrad	  (Fig.	  1)	  [7].	  	  
In	   humans,	   the	   Sec	   subfamily	   (SecGPx)	   is	   comprised	  of	   four	   tetrameric	   peroxidases	   (GPx1,	  GPx2,	  
GPx3,	   and	   GPx6)	   that	   use	   GSH	   to	   reduce	   H2O2	   and	   other	   small	   ROOH,	   including	   free	   fatty	   acid	  
hydroperoxides,	   and	   one	  monomeric	   peroxidase,	  GPx4	   that	   exhibits	   unusual	   preferences	   toward	  
both	   the	   oxidizing	   and	   the	   reducing	   substrates.	   Indeed,	   GPx4	   efficiently	   reduces,	   in	   addition	   to	  
small	   ROOH	   that	   are	   substrate	   for	   the	   tetrameric	   SecGPx,	   phospholipid	   and	   cholesterol	   or	  
cholesterol	   ester	   hydroperoxides	   incorporated	   in	   membranes	   or	   lipoproteins	   [8].	   Consequently,	  
unique	  among	  the	  SecGPx,	  GPx4	  is	  a	  vital	  enzyme	  preventing	  ferroptotic	  cell	  death	   in	  vivo,	  where	  
lipid	   peroxidation	   is	   involved	   [9,10].	   Nevertheless,	   GPx4	   also	   accepts	   protein	   thiols	   as	   electron	  
donors	  when	  GSH	  is	  limiting,	  a	  property	  related	  to	  its	  role	  in	  male	  fertility	  [11,12].	  However,	  recent	  
research	   suggests	   that	   all	   the	   SecGPx	   are	   relevant	   players	   in	   inflammation,	   cancer,	   proliferation,	  
signaling	  as	  reviewed	  in	  [13].	  As	  a	  whole,	  the	  importance	  of	  the	  SecGPx	  subfamily	  has	  contributed	  
to	  the	  perception	  of	  a	  multifaceted	  role	  of	  ROOH	  in	  cells.	  	  
_________________	  
 
1 Abbreviations:	   AKT,	   protein	   kinase	   B;	   BP,	   2,2’	   –bipyridyl;	   CysGPx,	   glutathione	   peroxidase	   containing	   cysteine	   as	   the	  
redox-­‐active	   moiety;	   DES,	   diethyl	   succinate;	   EPO,	   erythropoietin;	   ER,	   endoplasmic	   reticulum;	   ERK1/2,	   extracellular	  
regulated	  kinases	  1	  and	  2;	  ERO-­‐1,	  ER,	  oxidoreductin	  1;	  FGF,	  fibroblast	  growth	  factor	  –acidic;	  GPx,	  glutathione	  peroxidase;	  
GPx8,	  glutathione	  peroxidase	  family	  member	  8;	  HIF,	  hypoxia	  inducible	  factor;	  hGPx8,	  gene	  encoding	  human	  glutathione	  
peroxidase	  8,	  HRE,	  hypoxia	  response	  elements;	  c-­‐JNK,	  Jun	  NH(2)-­‐terminal	  kinase; MAPK,	  mitogen-­‐activated	  protein	  kinase,	  
NOX4,	   NADPH	   oxidase	   family	   member	   4;	   PLOOH,	   phospholipid	   hydroperoxide;	   PTEN,	   tensin	   homolog	   deleted	   on	  
chromosome	   10;	   PTP,	   protein	   tyrosine	   phosphatase;	   PTP1B,	   PTP	   family	   member	   1B;	   ROOH,	   hydroperoxide;	   P-­‐AKT,	  
phosphorylated	   protein	   kinase	   B;	   PGK,	   phosphoglycerate	   kinase;	   PDI,	   protein	   disulfide	   isomerase;	   P-­‐ERK1/2,	  
phosphorylated	   extracellular	   regulated	   kinases	   1	   and	   2;	   PKA,	   protein	   kinase	   A;	   Prx4,	   peroxiredoxin	   4;	   TK,	   thymidine	  
kinase;	   SecGPx,	   glutathione	   peroxidase	   containing	   selenocysteine	   as	   the	   redox-­‐active	   moiety;	   RTK,	   receptor	   tyrosine	  
kinase;	  PTEN,	  tensin	  homolog	  deleted	  on	  chromosome	  10	  
The	  Cys	  subfamily	  (CysGPx)	  is	  comprised,	  in	  humans,	  of	  three	  members	  that	  have	  been	  much	  less	  
studied	  than	  the	  SecGPxs.	  Structurally,	  two	  are	  monomeric	  proteins,	  namely	  GPx7	  and	  GPx8	  [14,15]	  
and	   one,	   GPx5,	   is	   a	   tetrameric	   enzyme	   specifically	   secreted	   from	   the	   epididymis	   [16]	   (Figure	   1).	  
GPx7	  and	  GPx8	  are	  the	  last	  discovered	  members	  and	  thus	  among	  the	  most	  mysterious	  in	  terms	  of	  
function.	  Evolutionary	  studies	  suggested	  that	  they	  derived	  from	  the	  SecGPx4,	  which	  actually	  had	  a	  
Cys-­‐containing	   ancestor.	   Thus,	   human	  GPx7	   and	  GPx8	   represent	   a	   recent	   return	   to	   Cys	   usage	   in	  
glutathione	  peroxidases,	  which	  is	  not	  easily	  rationalized	  [17].	  	  
Overall,	  steady-­‐state	  kinetic	  studies	  of	  various	  Cys	  variants	  of	  glutathione	  peroxidases	  indicate	  that	  
the	  step	  reducing	  ROOH	  is	  not	  dramatically	  affected	  by	  replacing	  Sec	  by	  Cys.	  This	  contrasts	  with	  the	  
reducing	  step	  by	  glutathione	  regenerating	  the	  ground	  state	  enzyme,	  which	  is	  much	  slower	  and	  
severely	  affects	  the	  enzyme	  turnover	  [7,18].	  Yet,	  the	  artificially	  constructed	  CysGPx4	  can	  rescue	  the	  
death	  phenotype	  of	  SecGPx4	  lacking	  cells	  [19]	  demonstrating	  that	  a	  Cys	  to	  Sec	  replacement	  does	  
not	  prevent	  the	  vital	  functions	  of	  the	  enzyme,	  at	  least	  in	  cells.	  
	  
GPx7	  and	  GPx8	  are	  widely	  distributed	  in	  mammals.	  Unique	  among	  the	  glutathione	  peroxidases	  family	  
members,	  they	  both	  contain	  an	  endoplasmic	  reticulum	  (ER)	  retention	  signal	  at	  the	  protein	  C-­‐terminal	  
end	  (Fig.	  1).	  GPx7	  is	  free	  in	  the	  lumen	  while	  GPx8	  is	  an	  intrinsic	  membrane	  peroxidase	  with	  its	  active	  
site	   facing	   the	   lumen	   [15,20].	   Peculiarly,	   they	   may	   accept	   protein	   disulfide	   isomerase	   (PDI)	   as	   a	  
reductant	  more	  efficiently	  than	  GSH	  [15,18,21].	  
The	  ER	   location	  and	  reactivity	  with	  PDI	  prompted	  the	  proposal	  that	  GPx7	  and	  GPx8	  are	   involved	   in	  
oxidative	   protein	   folding.	   This	   apparently	   occurs	   by	   re-­‐oxidizing	   PDI	   in	   the	   peroxidatic	   reaction,	  
where	  H2O2,	  produced	  by	  ER	  oxidoreductin	  (ERO-­‐1),	  is	  the	  oxidant	  [15,21].	  Peroxiredoxin	  4	  (Prx4),	  a	  
peroxidase	   present	   in	   the	   ER	   in	  most	   tissues	   as	   a	   secretory	   protein	   [22],	   is	   apparently	  much	   less	  
efficient	   in	   removing	   ER	   H2O2	   compared	   with	   GPx7	   and	   GPx8	   [15,21,23].	   Furthermore,	   kinetic	  
analysis	   shows	   that	   recombinant	   GPx7	   may	   reduce	   both,	   H2O2	   or	   phospholipid	   hydroperoxide	  
(PLOOH)	  by	  both,	  GSH	  or	  PDI,	  where	  kinetic	  constant	  measurements	  and	  concentration	  of	   the	  two	  
reductants	  within	  the	  ER	  comply	  with	  the	  proposal	  that	  the	  actual	  GSH	  concentration	  within	  the	  ER	  
might	  modulate	  PDI	  oxidation	  [18].	  On	  the	  other	  hand,	  whether	  reduction	  of	  PLOOH	  is	  a	  functional	  
role	  in	  GPx7	  physiology	  remains	  to	  be	  addressed.	  
GPx7	   has	   been	   described	   as	   a	   tumor	   suppressor.	   Together	   with	   human	   GPx3,	   the	   human	   GPx7	  
promoter	  was	  found	  hyper-­‐methylated	  and	  thus	  down-­‐regulated	  in	  some	  premalignant	  lesions	  of	  the	  
esophagus	   [24].	   Furthermore,	   in	   the	   epithelial	   cells	   of	   the	   esophagus,	   GPx7	   could	   protect	   against	  
oxidative	   damage	   of	   DNA	   and	   regulate	   oxidative	   signals	   that	   depend	   on	   the	   mitogen	   activated	  
protein	  kinases	  (MAPK)	  p38MAPK	  and	  c-­‐Jun	  NH(2)-­‐terminal	  kinase (JNK)	  upon	  exposure	  to	  pH	  4	  and	  
bile	   acids	   [25].	  More	   recently,	   it	  was	  documented	   that	   loss	   of	  GPx7	   resulted	   in	   systemic	   oxidative	  
damage,	   shortened	   life	   span	   and	   increased	   carcinogenesis	   in	   mice	   [26].	   Furthermore,	   GPx7	  
deficiency	   has	   been	   linked	   to	   obesity	   and	   pre-­‐adipocyte	   differentiation	   [27]	   by	   controlling	   the	  
dimerization	  of	  protein	  kinase	  A	  (PKA)	  and	  activating	  the	  CCAAT/enhancer	  binding	  protein	  beta.	  
Compared	   to	   GPx7,	   knowledge	   on	   GPx8	   is	   much	   more	   limited.	   The	   enzyme	   has	   not	   been	   fully	  
characterized	  kinetically,	  although	  it	  seems	  less	  efficiently	  reduced	  by	  PDI	  than	  GPx7	  [15].	  Apparently,	  
however,	  GPx8	  efficiently	  prevents	  the	  spillover	  of	  H2O2	  generated	  from	  the	  ER	  by	  ERO-­‐1	  [23].	  GPx8	  
was	   described	   as	   one	   of	   the	   cellular	   substrate	   of	   the	   Hepatitis	   C	   virus	   NS3-­‐4A	   protease	   [20]	   and,	  
according	   to	   a	   transcriptomic	   and	   proteomic	   profiling	   of	   KEAP1,	   it	   is	   down-­‐regulated	   in	   breast	  
epithelial	  sulforaphane-­‐treated	  cells,	  which	  suggests	  that	  Nuclear	  factor	  (erythroid-­‐derived	  2)-­‐like	  2	  
(Nrf2)	  indirectly	  dampens	  GPx8	  expression	  [28].	  
The	   studies	   presented	   here	   were	   designed	   to	   address	   the	   physiological	   function	   of	   GPx8	   by	  
examining	   the	   functionality	   of	   two	   Hypoxia	   Inducible	   Factor	   (HIF)	   binding	   sites	   in	   the	   promoter.	  
Indeed	   little	   is	   known	   about	   the	   link	   between	   HIF	   and	   glutathione	   peroxidases.	   Only	   the	   human	  
plasma	   glutathione	   peroxidase	   (GPx3)	   was	   described	   to	   contain	   a	   binding	   site	   for	   HIF-­‐1	   and	   it	   is	  
indeed	   induced	   by	   hypoxia	   [29].	   Similarly	   the	   expression	   of	   the	   human	  GPx1	  was	   found	   linked	   to	  
oxygen	  sensing,	  but	  through	  the	  action	  of	  two	  oxygen	  responsive	  promoter	  elements	  (ORE)	  [30].	  ORE	  
is	  distinct	   from	  hypoxia	  response	  element	   (HRE)	  and	  apparently	  responds	  to	  a	  milder	  hypoxia	   [31].	  
Notably,	  however	  the	  HIF	  subunits	  are	  not	  only	  stabilized	  by	  hypoxia,	  but	  by	  signaling	  as	  well,	  where	  
most	  likely	  common	  triggers	  are	  reactive	  nitrogen	  and	  oxygen	  species	  [32].	  We	  discovered	  that	  GPx8	  
is	   indeed	  a	  HIF	   target	  and,	  as	   such,	  up-­‐regulated	  by	  chemical	  hypoxia	  and	   fibroblast	  growth	   factor	  
(FGF)	  treatment.	  Furthermore,	  GPx8	  depletion	  in	  cells	  affected	  FGF	  and	  insulin	  signaling.	  All	  together	  
these	  findings	  link	  the	  expression	  of	  GPx8	  to	  HIF	  stabilization,	  and	  expand	  its	  function	  to	  the	  control	  
of	  RTK	  signaling	  cascades.	  	  
	   	  
Material	  and	  Methods	  
	  
Cell	  culture	  and	  treatments	  
	  
HeLa	  cells	   (ATCC	  CCL-­‐2TM)	  were	  cultured	   in	  DMEM	  supplemented	  with	  10%	  heat-­‐inactivated	   fetal	  
bovine	   serum	   (FBS),	   100	   U/ml	   penicillin,	   0.1	   mg/ml	   streptomycin	   and	   2	   mM	   L-­‐glutamine	   (Life	  
Technologies).	  Treatments	  were	  performed	  on	  70	  %	  confluent	  cells	  after	  overnight	  starvation	  in	  the	  
absence	  of	  FBS.	  To	  stabilize	  HIFα	  subunits,	  20	  mM	  diethyl	  succinate	  (DES)	  or	  0.1	  mM	  2,2’	  –bipyridyl	  
(BP)	  (Sigma)	  was	  added	  and	  cells	  further	  incubated	  in	  serum-­‐free	  medium	  for	  approximately	  16-­‐h.	  
In	  some	  experiments,	  100	  ng/ml	  of	  recombinant	  human	  fibroblast	  growth	  factor	  –	  acidic	  (FGF)	  (Life	  
technology),	  was	  used	  in	  serum-­‐free	  medium	  for	  30	  min	  and	  cells	  collected	  after	  24-­‐h	  in	  complete	  
medium.	  	  
GPx8	   silenced	   HeLa	   cells	   contained	   a	   vector	   for	   stable	   expression	   of	   small	   interfering	   RNA	  
addressed	  to	  GPx8	   (SilenciX	   technology)	  and	  were	  purchased	   from	  Tebu-­‐bio,	  which	  also	  provided	  
HeLa	  cells	  transfected	  with	  a	  control	  shRNA.	  The	  percentage	  of	  silencing	  was	  97%,	  as	  quantified	  by	  
the	  manufacturer.	  GPx8	  silenced	  cells	  and	  controls	   thereof	  were	  grown	  as	  above	  except	   that	   the	  
medium	   contained	   4	  mM	   L-­‐	   glutamine,	   110	  mg/l	   sodium	   pyruvate	   and	   125	   µg/ml	   hygromycin	   B	  
(Life	   Technologies).	   These	  were	   treated	  with	  100	  ng/ml	  of	   FGF	  or	   20	  µg/ml	   insulin	   for	   10	  min	   in	  
serum	   free	   medium	   and	   lysed	   as	   described	   below.	   Proteins	   were	   quantified	   by	   the	   Bradford	  
reagent	  (Sigma).	  
	  
mRNA	  analysis	  and	  quantification	  
	  
RNA	   was	   extracted	   by	   TRIzol	   reagent	   (Life	   Technology)	   and	   retrotranscribed	   using	   the	   Taqman	  
reverse	   transcription	   reagent	   (Applied	   Biosystem).	   Retrotranscribed	   RNA	   (100	   ng)	   was	   amplified	  
using	  the	  QuantumRNA	  Classic	  II	  18S	  (Life	  Technology)	  in	  the	  presence	  of	  5%	  dimethyl	  sulfoxide	  and	  
1	   µM	   of	   the	   HsGPx8-­‐fw	   and	   HsGPx8-­‐rev	   primers	   (Table	   1).	   Normalization	   was	   achieved	   by	  
measuring	   18S	   RNA.	   The	   annealing	   temperature	  was	   59	   °C.	   A	   Kodak	   image	   station	  was	   used	   for	  




The	   pGL3PGKHRE	   containing	   six	   repetitions	   of	   the	   human	   phosphoglycerate	   kinase	   (PGK)	   HREs	  
upstream	   the	   thymidine	   kinase	   (TK)	   promoter	   is	   described	   in	   [33].	   The	   pGL3-­‐based	   luciferase	  
reporter	   pGL3GPx8wt,	   which	   contains	   the	   two	   putative	   GPx8-­‐HRE1	   and	   GPx8-­‐HRE2	   in	   a	   pGL3Basic	  
vector	  (Promega)	  was	  obtained	  by	  cloning	  a	  1373	  bp	  fragment	  (from	  nt	  -­‐1391	  to	  -­‐18)	  of	  the	  human	  
GPx8	  promoter	  into	  the	  KpnI	  and	  BglII	  sites	  of	  the	  pGL3Basic	  vector.	  The	  fragment	  was	  obtained	  by	  
PCR	  from	  the	  genomic	  DNA	  obtained	  from	  white	  blood	  cells	  using	  the	  pGL3GPx8wt	  -­‐fw	  and	  pGL3GPx8wt-­‐
rev	  primers	  (Table	  1).	  
The	   constructs	   carrying	   mutations	   at	   the	   GPx8-­‐HRE1	   or	   GPx8-­‐HRE2	   or	   both	   the	   cassettes	  
(pGL3GPx8mut1,	   pGL3GPx8mut2,	   	   and	   pGL3GPx8mut1-­‐2	   respectively),	   	   were	   generated	   by	   PCR	   using	   Quick	  
change	   II	  according	   to	   the	  manufacturer’s	   instructions	   (Agilent	  Technologies,	  Santa	  Clara,	  CA,	  USA)	  
using	   the	   pGL3GPx8mut1-­‐fw	   and	   pGL3GPx8mut1-­‐rev	   	   or	   	   pGL3GPx8mut2-­‐fw	   and	   pGL3GPx8mut2-­‐rev	   nucleotides	  
respectively	  (Table	  1).	  In	  pGL3GPx8mut1,	  the	  GPx8-­‐	  HRE1	  wild	  type	  ‘ACGTG’	  cassette	  is	  exchanged	  with	  
‘TTAAT’.	  Similarly,	   in	  the	  pGL3GPx8mut2,	  the	  GPx8-­‐HRE2	  wild	  type	  ‘GCGTG’	  cassette	   is	  exchanged	  with	  
‘TTAAT’.	   The	   pGL3GPx8mut1-­‐2	   contains	   both,	  GPx8-­‐HRE1	   and	  GPx8-­‐HRE2,	   exchanged	  with	   the	   ‘TTAAT’	  
sequence	  and	  was	  obtained	  by	  subsequent	  mutation	  of	  the	  GPx8-­‐HRE2	  cassette	  of	  the	  pGL3GPx8mut1	  
by	  the	  above	  technique	  with	  the	  primers	  pGL3GPx8mut2-­‐fw	  and	  pGL3GPx8mut2-­‐	  rev	  (Table	  1).	  Constructs	  
accuracy	  was	  verified	  by	  sequencing.	  
	  
Cell	  transfection	  and	  reporter	  gene	  experiments	  
	  
HeLa	  cells	  were	  seeded	  onto	  24-­‐well	  plates,	  grown	  to	  60	  %	  confluence,	  and	  transfected	  with	  0.2	  µg	  
of	  the	  experimental	  constructs	  and	  the	  same	  amount	  of	  pRL-­‐TK	  vector	  expressing	  Renilla	  luciferase	  
(Promega)	   for	   control	   of	   transfection	   efficiency-­‐	   as	   described	   in	   [34],	   except	   that	   TransIT-­‐LT1	  
(Mirus)	  was	  used	  as	  transfection	  reagent.	  Firefly	   luciferase	  activity	  of	  the	  experimental	  constructs	  
was	   normalized	   to	   the	   Renilla	   luciferase	   activity	   obtained	   with	   the	   control	   vector	   pRL-­‐TK	   and	  
expressed	   as	   fold	   increase	   of	   luciferase	   activity.	   This	   is	   the	   ratio	   between	   the	   normalized	  
luminescence	  observed	   in	   the	   treated	   sample	  and	   that	   in	   the	   control	   sample,	  which	  was	   treated	  
with	   vehicle.	   In	   the	   experiments	  where	   transient	   expression	   of	  human	  HIF1α	  subunits	  was	   used,	  
the	   cotransfection	  mixture	   contained,	   beside	   the	   appropriate	  experimental	   construct	   and	   pRL-­‐TK	  
vector,	  0.2	  µg	  of	  a	  construct	  expressing	  stable	  HIF1α	  or	  HIF2α	  [33]	  and	  were	  collected	  after	  48-­‐hr.	  	  
In	   the	  experiments	  where	  the	  HIFα	   subunits	  were	  silenced,	  HeLa	  cells	  were	  first	   transfected	  with	  
the	   oligonucleotides	   SiRNA-­‐HIF1α−sense	   or	   SiRNA-­‐HIF2α−sense	   (Table	   1)	   and	   corresponding	  
antisense,	  for	  HIF1α	  or	  HIF2α	  silencing,	  respectively,	  by	  the	  TransIT	  –siQuest	  transfection	  reagent	  
(Mirus).	   Controls	   were	   produced	   by	   transfecting	   SiRNA-­‐scramble-­‐sense	   and	   corresponding	  
antisense	   (Table	   1).	   After	   four	   hours,	   cells	   were	   transfected	   with	   the	   experimental	   luciferase	  
reporter	   construct	   as	   described	   above,	   and	   20mM	  DES	  was	   used	   to	   stabilize	  HIFα	   subunits.	   The	  
effectiveness	  of	  siRNA	  treatment	  was	  verified	  by	  PCR	  on	  extracted	  and	  retrotranscribed	  RNA	  (see	  
above)	   from	   silenced	  HeLa	   cells	   using	   the	   primers	  HsHIF1α−fw	   and	  HsHIF1α−rev	   or	  HsHIF2α−fw	  
and	  HsHIF2α−rev	  (Table	  1).	  
	  
Nuclear	  extracts	  preparation	  and	  EMSA	  analysis	  
	  
HeLa	  cells	  were	  treated	  with	  DES	  or	  BP	  or	  vehicle	  as	  above,	  and	  the	  nuclear	  extract	  were	  prepared	  
according	   to	   [35],	  except	   that	   cells	  were	  collected	   in	  hypotonic	  buffer	  and	   immediately	   frozen	   in	  
liquid	  nitrogen	  before	  starting	  the	  nuclear	  preparation.	  Before	  use,	  the	  nuclear	  extract	  was	  dialyzed	  
by	  a	  8	  kDa	  cutoff	  mini	  dialysis	  kit,	  (GE	  Healthcare	  Biosciences).	  	  
EMSA	  analysis	  was	  performed	  using	  the	  LightShift	  Chemiluminescent	  EMSA	  kit	  (Thermo	  Scientific)	  
and	   used	   according	   to	   the	   manufacturer’s	   instructions.	   Biotinylated	   oligonucleotide	   probes	   of	  
identical	  length	  were	  used.	  These	  contained	  the	  GPx8-­‐HRE1	  and	  GPx8-­‐HRE2.	  As	  a	  positive	  control	  a	  
biotinylated	  probe	  of	   the	   same	   length	   containing	   four	   repetitions	   of	   EPO-­‐HREs	  was	   used.	   (GPx8-­‐
HRE1-­‐fw,	  GPx8-­‐HRE1-­‐rev;	  GPx8-­‐HRE2-­‐fw,	  GPx8-­‐HRE2-­‐rev,	  EPO-­‐HREs-­‐fw,	  EPO-­‐HREs-­‐rev	   in	  Table	  1).	  
Nuclear	   extract	   (7	   µg	   of	   proteins)	  was	   used	   for	   the	   binding	   reaction.	  When	   present,	   competitor	  
DNAs	   were	   pre-­‐incubated	   with	   the	   nuclear	   extract	   before	   adding	   the	   biotinylated	   probe.	  
Electrophoresis	  was	  performed	  on	  6	  %	  non-­‐denaturing	  polyacrylamide	  gels	  (DNA	  retardation	  gels,	  
Life	  Technologies)	  
	  
Preparation	  of	  cellular	  extracts,	  immunoblot	  analysis	  and	  quantification	  
	  
After	  treatments,	  HeLa	  cells,	  GPx8	  -­‐	  silenced	  HeLa	  cells	  and	  controls	  were	   lysed	  by	  0.1	  M	  Tris-­‐HCl	  
(pH	   7.5),	   150	   mM	   KCl,	   1	   mM	   EDTA,	   0.5	   %	   Triton	   X-­‐100	   and	   1	   %	   protease	   inhibitors	   (Protease	  
Inhibitor	  Cocktail,	  Sigma)	  and	  phosphatases	  Inhibitor	  (Phosphatase	  Inhibitor	  Cocktail	  2,	  Sigma).	  The	  
whole	  extract,	   containing	  approximately	  20	   to	  40	  µg	  of	  protein,	  was	  dissolved	   in	   Laemmli	   buffer	  
containing	  1	  M	  2-­‐mercaptoethanol,	  denatured	  at	  95	   0C	  and	  resolved	  on	  a	  NuPage	  4–12	  %	  BisTris	  
mini	  gel	  (Life	  Technologies)	  and	  transferred	  to	  a	  nitrocellulose	  membrane	  using	  a	  buffer	  containing	  
25	  mM	  ethanolamine,	  104	  mM	  glycine,	  20	  %	  methanol,	  pH	  9.5.	  After	  an	  overnight	  blotting	  at	  180	  
mA,	   the	   nitrocellulose	   membrane	   was	   appropriately	   cut	   and	   immunoblotted	   with	   specific	  
antibodies	  against	  GPx8	  (Abnova),	  PDI	  (BD	  Transduction	  Laboratories),	  phosphorylated	  extracellular	  
signal	   regulated	   kinase	   1/2	   (P-­‐ERK1/2,	   pT42	   and	   pY44),	   (Santa	   Cruz	   Biotechnology)	   or	  
phosphorylated	   protein	   kinase	   B	   (P-­‐AKT,	   pS473)	   (Cell	   Signaling	   Technology)	   or	   anti	   HSP90	  
α/β  (Santa	  Cruz	  Biotechnology).	  
For	  ERK1/2	  detection,	  the	  blotting	  probed	  with	  P-­‐ERK	  was	  stripped	  and	  re-­‐probed	  with	  antibodies	  
against	   ERK1/2	   (Santa	   Cruz	   Biotechnology).	   Immunoreactive	   bands	   were	   detected	   using	  
appropriate	   secondary	   antibodies	   conjugated	   to	   HRP	   (Santa	   Cruz	   Biotechnology)	   followed	   by	  
chemiluminescence	  detection	  on	  a	  Kodak	  Image	  station.	  
	   	  
Results	  
	  
The	  promoter	  of	  GPx8	  contains	  two	  putative	  Hypoxia	  Response	  Elements	  (HREs)	  	  
	  
In	  2010,	  the	  promoters	  of	  all	  the	  glutathione	  peroxidases	  were	  screened	  by	  an	  optimized	  analysis	  
method	   for	   transcription	   factor	   binding	   sites,	   which	   matched	   different	   searching	   programs,	   i.e.	  
Match,	  P-­‐Match,	  MatInspector	  [36].	  The	  promoter	  of	  GPx8	  emerged	  as	  a	  possible	  HIF	  target	  since	  
two	   conserved	   HREs	   were	   predicted	   by	   comparing	   various	   GPx8	   sequences	   from	   different	  
mammals.	  Supported	  by	  the	  observation	  that,	  in	  the	  human	  gene,	  these	  two	  putative	  HREs	  (GPx8-­‐
HRE1	  and	  GPx8-­‐HRE2,	  Fig.	  2)	  exactly	  match	  the	  HIF-­‐	  DNA	  binding	  motif	  (5’-­‐RCGTG-­‐3’)	  described	  in	  
[32],	   we	   recently	   decided	   to	   address	  whether	   the	   human	  GPx8	   is	   a	   HIF	   target	   and	  whether	   the	  
predicted	  GPx8-­‐HRE1	  and	  GPx8-­‐HRE2	  are	  functional	  sites	  in	  the	  human	  gene	  (hGPx8).	  
	  
hGPx8	  mRNA	  and	  protein	  are	  induced	  by	  HIF	  alpha	  stabilization	  
	  
We	   first	   addressed	  whether,	   in	   cultured	   cells,	   the	   amount	   of	  GPx8	  mRNA	   is	   increased	  when	  HIF	  
alpha	  subunits	  are	  stabilized.	  To	  this	  end,	  HeLa	  cells	  were	  treated	  with	  BP	  or	  DES,	  which	  stabilize	  
HIFα	  subunits	  by	  HIF	  prolyl	  4-­‐hydroxylase	  inhibition	  [37,38].	  Fig.	  3	  shows	  that	  both	  GPx8	  mRNA	  and	  
protein	  are	  significantly	   increased	  following	  cell	   treatment	  with	  either	  100	  µM	  BP	  or	  20	  mM	  DES,	  
indicating	  that	  HIFα	  stabilization	  results	  in	  increased	  GPx8	  expression.	  	  
	  
Both	  the	  HREs	  within	  the	  hGPx8	  are	  functional	  
	  
Next,	  we	  addressed	  whether	  the	  fragment	  of	  the	  promoter	  containing	  the	  putative	  GPx8-­‐HRE1	  and	  
GPx8-­‐HRE2	  could	  support	  GPx8	  transcriptional	  activation,	  and	  whether	  the	  two	  HREs	  are	  involved.	  
To	  this	  purpose	  reporter	  gene	  experiments	  were	  conducted.	  First,	  pGL3GPx8wt,	  a	  luciferase	  reporter	  
containing	  a	   fragment	  of	  1373	  nt	  upstream	  the	   transcriptional	   start	  of	  GPx8	   (from	   -­‐18	   to	   -­‐1391),	  
containing	  the	  two	  putative	  HREs,	  was	  used	  for	  transfecting	  HeLa	  cells.	  Following	  a	  treatment	  with	  
DES	   or	   BP,	   luciferase	   activity	  was	  measured.	   As	   a	   positive	   control,	   cells	  were	   transfected	  with	   a	  
luciferase	  reporter	  containing	  six	  repetitions	  of	  the	  PGK	  HRE	  upstream	  the	  TK	  promoter	  (PGL3PGKHRE)	  
[33],	  a	  well	  -­‐	  known	  HIFα	  target.	  
As	   shown	   in	   Fig.	   4A	   both,	   DES	   or	   BP	   treatment	   increased	   luciferase	   activity	   five	   or	   four	   times	  
respectively	  in	  pGL3GPx8wt	  -­‐	  transfected	  cells.	  An	  increase	  of	  approximately	  two	  or	  three	  times	  was	  
also	   observed	   respectively	   in	   both,	   DES	   or	   BP-­‐treated	   cells	   transfected	   with	   pGL3PGKHRE.	   In	   cells	  
transfected	  with	  pGL3GPx8wt	   or	   pGL3PGKHRE	   luciferase	   activity	  was	   also	   increased	  by	   co-­‐transfection	  
with	  stable	  HIF1α	  or	  HIF2α	   (Figure	  4B).	  We	  concluded	  that	   the	  examined	   fragment	  of	   the	  hGPx8	  
promoter	  could	  drive	  transcription	  following	  HIF	  alpha	  subunits	  stabilization.	  Next,	  an	  experiment	  
similar	   to	   that	   in	   Fig.	   4A	  was	   conducted,	   but	   plasmids	   carrying	   individual	  mutation	   at	   the	  GPx8-­‐
HRE1	  or	  GPx8-­‐HRE2,	  or	  at	  the	  two	  sites	  simultaneously,	  pGL3GPx8mut1,	  pGL3GPx8	  mut2	  and	  pGL3GPx8	  mut1-­‐2	  
respectively,	  were	  also	  used	  (Fig.	  5).	  Luciferase	  activity	  dropped	  from	  30	  to	  70	  %	  in	  the	  DES	  -­‐	  or	  BP	  -­‐	  
treated	   cells	   containing	   the	  mutated	   constructs.	  Notably	   however,	   the	   cells	   transfected	  with	   the	  
pGL3GPx8mut1,	   containing	   the	   GPx8-­‐HRE2	   site	   only,	   exhibited	   a	   significant	   higher	   inhibition	   when	  
compared	   to	   those	   transfected	  with	   pGL3GPx8mut2,	   containing	  GPx8-­‐HRE1	  only,	   suggesting	   a	  major	  
role	   of	   the	   GPx8-­‐HRE1	   site	   in	   promoting	   expression.	   In	   the	   cells	   transfected	   with	   the	   double	  
mutated	  construct	  pGL3GPx8	  mut1-­‐2,	   luciferase	  activity	   in	   response	   to	  DES	  or	  BP	  was	  not	   completely	  
inhibited,	   indicating	   that	  some	  flanking	  elements	  may	  have	  a	   role	   in	   the	  HIF-­‐driven	  expression	  of	  
GPx8	   or	   that	   DES	   or	   BP	   may	   cause	   some	   HIF-­‐independent	   luciferase	   expression.	   This	   was	   not	  
further	   investigated.	   Collectively,	   these	   experiments	   reveal	   that	   both	  GPx8-­‐HRE1	   and	  GPx8-­‐HRE2	  
are	  novel	  functional	  sites	  in	  HeLa	  cells,	  GPx8-­‐HRE1	  having	  a	  major	  role.	  	  
	  
Nuclear	  extracts	  containing	  stabilized	  HIFα	  exhibit	  binding	  activity	  with	  GPx8-­‐HRE1	  and	  GPx8-­‐HRE2	  
	  
Whether	   the	   two	  HREs	   directly	   bind	   to	   stabilized	   nuclear	   HIF	   was	   addressed	   by	   gel	   retardation	  
assay.	  Two	  distinct	  synthetic	  fragments	  encompassing	  respectively	  the	  GPx8-­‐HRE1	  and	  GPx8-­‐HRE2	  
were	   incubated	   with	   nuclei	   obtained	   from	   DES	   or	   BP	   treated	   cells	   and	   subjected	   to	   EMSA.	   A	  
synthetic	  fragment	  encompassing	  the	  HRE	  of	  erythropoietin	  (EPO-­‐HRE)	  of	  identical	  length	  was	  used	  
as	  a	  positive	  control.	  EPO	  is	  indeed	  a	  well	  known	  HIF	  target	  [33].	  DES	  or	  BP	  treated	  nuclei	  yielded	  
an	  enhanced	  DNA	  binding	  activity	   to	  both	   the	  HREs	   (Figure	  6	  A	  and	  B,	   lanes	  3,	  4).	  Similarly,	  DES-­‐
treated	  nuclei	  yielded	  enhanced	  DNA	  binding	  to	  EPO-­‐HRE	  (Figure	  6	  C	  lane	  3),	  suggesting	  therefore	  
that	  stable	  HIF	  alpha	  is	  indeed	  the	  protein	  involved.	  This	  however	  could	  not	  be	  further	  verified	  by	  
super-­‐shift,	   since	   a	   suitable	   anti-­‐HIF	   antibody	   for	   this	   purpose	   was	   not	   found.	   However,	   the	  
observation	  that	  all	  protein	  -­‐	  fragments	  binding	  complexes	  migrated	  identically,	  strongly	  suggested	  
that	  HIF	  alpha	  is	  present	  in	  the	  complex	  (Figure	  6	  D).	  
Interestingly,	   the	   binding	   of	   HIFα	   to	  GPx8-­‐HRE1	   appears	   stronger	   than	   that	   to	  GPx8-­‐HRE2,	   as	   a	  
higher	  concentration	  of	  unlabeled	  probe	  was	  required	  to	  decrease	  the	  DNA	  binding	  activity	  in	  the	  
competition	  experiment	  (Figure	  6	  A,	  B,	  lanes	  5	  and	  6).	  Thus	  apparently	  both,	  GPx8-­‐HRE1	  and	  GPx8-­‐
HRE2,	  directly	  bind	  to	  stable	  HIF	  alpha,	  the	  GPx8-­‐HRE-­‐1	  site	  displaying	  higher	  affinity.	  
	  
The	  two	  HREs	  of	  GPx8	  are	  preferentially	  HIF2α	  targets	  	  
	  SiRNA	   technology	  was	   used	   to	   address	  which	   of	   the	   two	  HIFα	   subunits	   targets	   the	  HREs	   of	  GPx8.	  
Cells	  were	  silenced	  by	  siRNA	  directed	  to	  HIF1α	  or	  HIF2α,	  co-­‐transfected	  respectively	  with	  pGL3GPx8wt,	  
pGL3GPx8mut1,	   pGL3GPx8	  mut2	  and	   treated	  with	  DES.	   In	   control	   cells,	   scrambled	   siRNA	  was	   used	   for	   co-­‐
transfection.	  Luciferase	  activity	  measurements	  showed	  that	   increase	  of	   luciferase	  activity	  after	  DES	  
treatment	   is	   almost	   completely	   abrogated	   after	   HIF2α	   but	   not	   HIF1α	   silencing	   (Fig.	   7).	   Thus	  
apparently	  both	  GPx8-­‐HRE1	  and	  GPx8-­‐HRE2	  are	  preferentially	  HIF2α	  targets.	  
	  
GPx8	   resides	   in	   the	   ER	   where	   it	   is	   involved	   in	   oxidative	   protein	   folding	   by	   oxidizing	   PDI	   and	   GSH	  
[15,18,23].	  However,	  our	  observation	  that	  GPx8	  is	  among	  the	  plethora	  of	  HIFα - activated	  genes	  that	  
have	  critical	  roles	  in	  cell	  survival,	  proliferation,	  metabolism	  [39],	  together	  with	  the	  observation	  that	  
the	   ER	   is	   a	   critical	   player	   in	   signaling	   [40],	   prompted	   to	   investigate	  whether	   the	   peroxidase	   could	  
have	   a	   role	   in	   growth	   factors	   signaling.	   Because	   HIF1α	   synthesis	   is	   increased	   by	   signaling	   from	  
receptor	  tyrosine	  kinases	  (RTK)	  by	  the	  MAP	  kinase	  (MPK)	  pathways	  [32],	  we	  addressed	  whether	  FGF	  
treatment	  can	  increase	  GPx8	  expression.	  
	  
FGF	  increases	  GPx8	  expression	  	  
	  
Results	  in	  Fig.	  8A	  shows	  that	  GPx8	  mRNA	  is	  increased	  by	  FGF	  treatment	  in	  HeLa	  cells.	  In	  agreement,	  
under	  these	  conditions,	  cells	  bearing	  the	  reporter	  construct	  pGL3GPx8wt	  exhibit	  increased	  luciferase	  
activity	  following	  FGF	  treatment.	  A	  similar	  increase	  is	  also	  observed	  in	  the	  control	  cells	  transfected	  
with	   pGL3PGKHRE	   (Fig.	   8B),	   suggesting	   that,	   in	   our	   conditions,	   HIF	   is	   involved	   in	   the	   increased	  
expression	   of	   GPx8	   by	   FGF.	   On	   these	   bases	   we	   hypothesized	   that	   GPx8	   might	   have	   a	   role	   in	  
controlling	  FGF	  signaling	  and	  investigated	  this	  possibility	  
	  
Loss	  of	  GPx8	  up-­‐regulates	  FGF	  and	  insulin	  signaling	  
	  
To	   address	   the	   impact	   of	   GPx8	   in	   FGF	   signaling,	   we	   used	   HeLa	   cells	   stably	   expressing	   a	   SiRNA	  
targeted	  to	  GPx8	  and	  controls	  thereof	  and	  we	  measured	  the	  extent	  of	  phosphorylation	  of	  ERK1/2	  
following	  FGF	  treatment.	  To	  extend	  the	  observation	  to	  RTK	  signaling,	  we	  also	  focused	  on	  the	  insulin	  
signaling	  cascade.	  	  
Indeed	   silencing	   of	   GPx8	   increased	   phosphorylation	   of	   the	  MAP	   kinases	   ERK1/2	   induced	   by	   FGF	  
sixteen	  fold,	  suggesting	  that	  the	  peroxidase	  negatively	  regulates	  FGF	  signaling.	  Furthermore,	  GPx8	  
silenced	  cells	   responded	   to	   insulin	   treatment	  with	  an	   increased	  ERK1/2	  and	  AKT	  phosphorylation	  
(12	  and	  2.7	  fold	  respectively)	  (Figure	  9	  A	  and	  B).	  We	  concluded	  that,	  in	  HeLa	  cells,	  GPx8	  is	  a	  master	  
regulator	  of	  FGF	  and	  insulin	  signaling.	  
	   	  
Discussion	  
	  
This	  study	  reveals	  that	  HIF	  alpha	  subunits	  stabilizers,	  such	  as	  DES	  or	  BP	  that	  inhibit	  iron-­‐dependent	  
prolyl	  4-­‐hydroxylases	  by	  competitive	   inhibition	  or	   iron	  chelation	   respectively,	   increase	  expression	  
of	   GPx8,	   one	   of	   the	   mammalian	   Cys	   glutathione	   peroxidases	   of	   the	   ER.	   These	   treatments	   also	  
increase	   the	   activity	   of	   a	   luciferase	   reporter	   driven	   by	   a	   fragment	   of	   the	   GPx8	   promoter	  
encompassing	  the	  two	  putative	  HREs	  (pGL3GPx8wt),	  which	  are	  equally	  increased	  by	  overexpression	  of	  
stable	  HIF1α	  and	  HIF2α	  subunits.	  Similarly,	  activity	  of	  a	  luciferase	  reporter	  containing	  repetitions	  of	  
the	   HRE	   site	   of	   phosphoglycerate	   kinase	   (pGL3PGKHRE),	   an	   established	   HIF	   target,	   is	   increased.	  
Between	   the	   two	   sites,	  GPx8-­‐HRE1	  appears	   to	  have	   the	  dominant	   role.	  Mutating	   the	  GPx8-­‐HRE1	  
within	  pGL3GPx8wt	  produces	  a	  more	  pronounced	  drop	  of	   luciferase	  activity	  than	  does	  mutating	  the	  
GPx8-­‐HRE2.	   Furthermore,	   as	   demonstrated	   in	   a	   competitive	   gel	   retardation	   assay,	   inhibition	   of	  
binding	  of	  GPx8-­‐HRE1	  to	  a	  nuclear	  extract	  containing	  stabilized	  HIF	  requires	  a	  greater	  amount	  of	  an	  
unlabeled	  HIFα	  fragment,	  than	  does	  GPx8-­‐HRE2,	  indicating	  a	  higher	  affinity	  of	  GPx8-­‐HRE1	  to	  HIFα.	  
Collectively	   these	   results	   demonstrate	   that	  GPx8	   is	   a	   novel	   HIFα	   target	   and,	   by	   binding	   HIF	   and	  
promoting	   transcription,	  GPx8-­‐HRE1	   and	  GPx8-­‐HRE2	   are	   novel	   functional	   sites.	   Yet,	   they	   are	   not	  
identical,	  being	  endowed	  with	  individual	  activity	  and	  affinity.	  	  
Despite	  incomplete	  knowledge	  of	  how	  mammalian	  glutathione	  peroxidases	  are	  regulated,	  we	  know	  
that,	  at	   least	  one	  other	  glutathione	  peroxidase	  is	  a	  HIF	  target.	   Indeed,	  GPx3,	  a	  SecGPx	  resident	   in	  
plasma	   and	   extracellular	   fluids,	   contains	   one	   HIF	   binding	   site	   and	   is	   strongly	   up-­‐regulated	   by	  
hypoxia	  in	  renal	  cell	  lines	  [29].	  Interestingly,	  both	  GPx3	  and	  GPx8	  are	  linked	  to	  the	  ER,	  the	  former	  as	  
a	  peroxidase	  that	  travels	  this	  compartment	  in	  secretory	  cells,	  and	  the	  latter	  as	  a	  resident	  protein	  of	  
the	  ER	  membrane.	  However,	  not	  all	  of	  the	  ER	  glutathione	  peroxidase	  genes	  are	  HIF	  targets.	  Human	  
GPx7,	   which	   express	   the	   other	   CysGPx	   located	   in	   the	   soluble	   compartment	   of	   the	   ER,	   does	   not	  
contain	   conserved	   HREs	   and,	   accordingly,	   does	   not	   respond	   to	   HIF	   stabilizers	   (M.	   Maiorino,	  
unpublished),	   an	   observation	   highlighting	   that	   glutathione	   peroxidases	   are	   part	   of	   networks	  
subjected	  to	  distinct	  control	  mechanisms.	  
HIFs	  are	  αβ	  heterodimers,	  HIF1α	  and	  HIF2α	  being	  constitutively	  expressed	  and	  oxygen-­‐regulated	  at	  
the	   protein	   level	   and	   endowed	   of	   distinct	   roles	   [32,33,38,41].	   In	   DES-­‐treated	   cells,	   luciferase	  
activity	  of	  the	  pGL3GPx8wt	  or	  of	  the	  plasmids	  carrying	  mutation	  at	  HREs	  (pGL3GPx8mut1	  or	  pGL3GPx8mut2)	  
is	  almost	  completely	  abrogated	  when	  the	  HIF2α,	  but	  not	  the	  HIF1α	  subunit,	  is	  silenced	  (Figure	  7).	  
Apparently,	   therefore,	  both	   the	  HREs	  of	  GPx8	   are	  preferentially	  HIF2α	   targets.	   So	   far	   this	   finding	  
does	   not	   conflict	   with	   the	   observed	   increased	   luciferase	   activity	   in	   cells	   containing	   the	   reporter	  
pGL3GPx8wt	   upon	  HIF1α	   overexpression	   (Fig.	   4B).	   It	  was	   indeed	   already	  observed	   that	   target	   gene	  
specificity	  can	  be	  overcome	  by	   forced	  expression	  of	   the	  HIF	   subunits	   [33]	  and	   it	   is	  not	  a	   surprise	  
that	   overexpression	   overcomes	   affinity.	   GPx8	   emerges	   as	   a	   preferential	   target	   of	  
HIF2α, which	  drives	  the	  chronic	  response	  to	  hypoxia,	  opposite	  to	  HIF1α	  driving	  the	  initial	  response	  
[41],	  but	  it	  may	  well	  be	  a	  target	  of	  HIF1α 	  when	  concentration	  of	  the	  latter	  increases.	  	  
HIF	  is	  not	  only	  stabilized	  by	  hypoxia,	  apparently	  HIFα	  degradation	  is	  blocked	  by	  reactive	  oxygen	  and	  
nitrogen	   species	   and	   HIF1α synthesis	   is	   increased	   by	   increased	   signaling	   from	   RTK	   via	   mitogen	  
activated	  protein	  kinase	  (MAPK)	  pathway	  [32].	  The	  latter	  observations	  comply	  with	  our	  finding	  that	  
GPx8	   is	   transcriptionally	   activated	   by	   FGF,	   a	   cytokine	   acting	   on	   a	   RTK,	   which	   activates	   the	  
downstream	  MAPK	   ERK1/2	   (Figure	   7A).	   In	   this	   experiment,	   specific	   HIF	   involvement	   is	   deduced	  
because	  luciferase	  activity	  of	  both	  the	  reporters	  pGL3GPx8wt	  and	  pGL3PGKHRE	  that	  respond	  to	  chemical	  
HIF	   stabilizers	   or	   HIF	   subunits	   overexpression	   (see	   above	   and	   Fig.	   4),	   increases	   following	   FGF	  
treatment	  (Fig.	  8B).	  	  
Thus,	  as	  a	  HIF-­‐target	  gene	  GPx8	  is	  among	  the	  plethora	  of	  genes	  activated	  by	  the	  cytokines	  acting	  on	  
MAPK	  pathway,	  such	  as	  FGF.	  Whether	  other	  growth	  factors	  are	   involved	   in	   inducing	  GPx8	  via	  HIF	  
appears	  plausible,	  although	  it	  was	  not	  addressed	  in	  this	  study.	  	  
Our	   attempt	   to	   elucidate	   the	   functional	   relationship	   between	   GPx8	   and	   FGF	   or	   agonists	   that	  
activate	  RTK	  revealed	  that	  GPx8	  is	  indeed	  involved	  in	  down-­‐regulating	  these	  signaling	  cascades.	  	  
In	  GPx8-­‐depleted	  HeLa	  cells,	  FGF	  treatment	  increases	  ERK1/2	  phosphorylation,	  and	  similarly	  insulin	  
treatment	  increases	  phosphorylation	  of	  both	  ERK1/2	  and	  AKT	  (Fig.	  9).	  As	  an	  ER	  peroxidase,	  GPx8	  is	  
perhaps	  in	  a	  privileged	  location	  to	  control	  the	  flux	  of	  H2O2	  that	  specifically	   inactivates	  the	  protein	  
tyrosine	  phosphatase	  (PTP)	  family	  member	  PTP1B	  [42].	  Indeed	  PTP1B,	  which	  is	  apparently	  located	  
in	   the	   outer	   membrane	   of	   the	   ER	   [40,43],	   has	   been	   proposed	   to	   control	   the	   extent	   of	  
phosphorylation	   of	   both,	   RTK	   and	   insulin	   receptor	   substrate	   1	   (IRS-­‐1)	   [44],	   and	   thus	   the	  
phosphorylation	   status	   of	   both	   the	   downstream	   targets	   ERK	   and	   AKT	   that	   we	   find	   hyper-­‐
phosphorylated	  by	  insulin/FGF	  treatment	  in	  GPx8-­‐depleted	  cells.	  
The	  notion	  that	  glutathione	  peroxidases	  are	  involved	  in	  controlling	  signaling	  cascades	  by	  RTK,	  that	  
produce	   phosphatase-­‐inactivating	   H2O2	   via	   NADPH	   oxidase	   4	   (NOX4)	   and	   subsequent	   O2
-­‐	  
dismutation	   [40],	   is	   emerging.	   Insulin-­‐treated	   muscles	   from	   GPx1-­‐/-­‐	   mice	   show	   increased	   AKT	  
phosphorylation	  that,	   remarkably	   is	  not	  associated	  with	   increased	  phosphorylation	  of	  ERK1/2	  [5].	  
Therefore	  GPx1	  depletion	  affects	  the	  redox	  status	  of	  the	  phosphatase	  and	  tensin	  homolog	  deleted	  
on	  chromosome	  10	  (PTEN),	  which	  is	  a	  protein	  located	  mainly	  in	  cytosol	  and	  the	  nucleus	  [45]	  instead	  
of	  that	  of	  the	  ER-­‐residing	  PTP1B	  [5].	  It	  emerges	  therefore	  that	  the	  phosphatase	  targets	  are	  distinct	  
for	  the	  ER	  peroxidase	  GPx8	  or	  the	  cytosolic/mitochondrial	  GPx1.	  Our	  experiments	  brings	  into	  focus	  
that	   co-­‐localization	   in	   the	   ER	   of	   NOX4,	   GPx8	   and	   the	   phosphatase	   target,	   together	   with	   the	  
diffusible	  nature	  of	  H2O2,	  are	  of	  crucial	  importance	  in	  controlling	  signaling	  descending	  from	  PTP1B.	  
This	   implies	   that	   the	   other	   ER	   peroxidases	   might	   also	   have	   the	   role	   of	   down-­‐regulating	   PTP1B-­‐
dependent	   signaling	   as	   	  GPx8	  expression	  does.	   Experimental	   evidence	   thus	   far	   seems	   to	   support	  
this	   view.	   In	   esophageal	   cells,	   GPx7	   was	   shown	   to	   regulate	   oxidative	   signals	   that	   depend	   on	  
p38MAPK	  and	  JNK	  upon	  exposure	  to	  pH	  4	  and	  bile	  acids	   [25].	  Furthermore,	   transient	  silencing	  of	  
GPx7	   in	   HeLa	   cells	   increases	   ERK1/2	   phosphorylation	   similarly	   to	   depletion	   of	   GPx8	   (V.	   Bosello-­‐
Travain,	   unpublished).	   Perhaps	   also	   the	   tumor	   suppressor	   activity	   in	   prostate	   cancer	   cells	   of	   the	  
secretory	  SecGPx3	  [46]	  might	  be	  explained	  by	  such	  a	  mechanism.	  On	  the	  other	  hand,	  silencing	  of	  
the	  cytosolic	  GPx4	  does	  not	  affect	  ERK1/2	  signaling	   [47].	  Furthermore,	   the	  observation	  that	  GPx1	  
overexpression	  prevented	  ERK1/2	  phosphorylation	  after	  preconditioning	  neonatal	  mice	  brain	  with	  
non	   lethal	   hypoxia	   [48],	   does	   not	   contradict	   this	   view,	   but	   rather	   suggests	   that	   overexpression	  
allows	  more	  of	  GPx1	  to	  be	  closer	  to	  PTP1B	  on	  the	  cytosolic	  surface	  of	  the	  ER.	  	  
	   From	  the	  viewpoint	   that	  hypoxia	   is	  associated	  with	  enhanced	  RTK-­‐mediated	  signaling,	  which	  
contributes	  to	  oncogenesis	  and	  more	  aggressive	  disease	  [49-­‐51],	  the	  induction	  of	  GPx8	  expression	  
by	   HIF	   may	   be	   considered	   as	   an	   attempt	   to	   slow	   down	   an	   excessive	   proliferative	   signal	   during	  
oxygen	   deprivation	   and/or	   RTK	   signaling.	   Under	   these	   conditions,	   a	   fine-­‐tuning	   of	   growth	   and	  
metabolism	  is	  seemingly	  necessary.	  This	   is	  apparently	  achieved	  by	  the	   interplay	  between	  positive	  
and	  negative	  effectors	  [52],	  and,	  	  apparently,	  GPx8	  plays	  the	  latter	  role.	  	  
	   Whether	   data	   presented	   here	   are	   involved	   with	   the	   function	   of	   GPx8	   in	   oxidative	   protein	  
folding	   remains	   to	  be	  established.	   It	   is	  worth	   to	  mention,	   however,	   that	   among	   the	  hundreds	  of	  
genes	  that	  are	   induced	  by	  HIFα	   there	   is	  also	  ERO-­‐1	  [53],	  which	  produces	  H2O2	  for	  GPx8.	  The	  dual	  
role	  of	  GPx8	  in	  oxidative	  folding	  and	  signaling	  may	  suggest	  a	  link	  between	  the	  two	  processes.	  This	  
relationship	  awaits	  further	  research.	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Figure	  legends	  
	  
Fig.	  1	  Multiple	  alignment	  of	  the	  eight	  members	  of	  the	  human	  GPx	  family	  and	  GPx3	  from	  yeast,	  as	  an	  example	  
of	   the	   non-­‐vertebrate	   enzymes.	   Alignment	   has	   been	   obtained	   by	   clustal	  
(http://www.ebi.ac.uk/Tools/msa/clustalw2/)	   and	   manually	   edited.	   Amino	   acids	   whose	   identity	   threshold	   is	  
above	  80%	  are	  shaded	  in	  gray	  (the	  darker	  the	  most	  conserved).	  Triangles	  show	  the	  catalytic	  tetrad.	  Tetramer	  
and	  dimer	   interfaces	  for	  protein	  oligomerization	  are	   indicated.	  The	  Cys	  block,	  containing	  the	  resolving	  Cys	  of	  
the	  non-­‐vertebrate	  and	  plant	  members	  is	  also	  indicated.	  The	  N-­‐terminal	  signal	  peptide	  and	  the	  C-­‐terminal	  ER	  
retention	  sequence	  are	  boxed	  in	  the	  ER	  resident	  GPxs.	  
	  
Fig.	  2.	  Location	  and	  sequence	  of	  the	  putative	  hypoxia	  response	  elements	  (HRE)	  within	  the	  promoter	  of	  human	  
GPx8	  (hGPx8).	  A	  1400	  nucleotides	  fragment	  upstream	  the	  hGPx8	  ATG	  translation	  containing	  the	  two	  putative	  
HREs	  is	  shown.	  These	  are	  located	  at	  -­‐1298	  and	  -­‐	  898	  from	  the	  ATG.	  They	  precisely	  fit	  the	  consensus	  sequence	  -­‐
RCGTG-­‐	  for	  HIF	  α	  [32],	  R	  is	  A	  in	  GPx8-­‐	  HRE1	  and	  G	  in	  GPx8-­‐HRE-­‐2.	  	  
Fig.	  3.	  HIFα	  subunits	  stabilization	  increases	  GPx8	  mRNA	  (A)	  and	  protein	  (B)	  expression.	  HeLa	  cells	  were	  treated	  
in	  triplicate	  respectively	  with	  20	  mM	  DES	  or	  0.1	  mM	  BP,	  for	  18	  hours,	  to	  stabilize	  HIFα 	  subunits.	  Control	  cells	  
were	  treated	  with	  vehicle	  (V).	   In	  (A)	  RNA	  was	  extracted,	  retrotranscribed	  and	  probed	  by	  PCR,	  as	  described	  in	  
Methods.	  The	   internal	  control	  was	  18S	  RNA.	  Expected	   length	  of	   the	   fragment	  of	  GPx8	   is	  516	  bp,	   that	  of	  18S	  
RNA	   320	   bp.	   Band	   intensity	   of	   GPx8	   was	   normalized	   to	   18S	   RNA	   and	   fold	   increase	   of	   GPx8	   mRNA	   was	  
calculated	  as	  the	  ratio	  between	  normalized	  GPx8	  expression	  in	  experimental	  sample	  vs	  control	  (vehicle).	  One	  
of	   five	   independent	   experiments	   with	   similar	   results	   is	   reported.	   In	   (B)	   cells	   were	   lysed	   in	   the	   presence	   of	  
protease	   inhibitors	   and	   20	   µg	   of	   the	   protein	   extract	  was	   subjected	   to	   SDS-­‐PAGE	   followed	   by	  Western	   blot,	  
which	   was	   decorated	   overnight	   by	   anti-­‐GPx8	   (αGPx8)	   or,	   for	   1	   hour,	   by	   anti-­‐PDI	   (αPDI)	   antibodies.	  
Immunoreactive	  bands	  were	  detected	  and	  quantified	  (see	  Methods	  for	  details).	  The	  intensity	  of	  the	  GPx8	  band	  
was	  normalized	  to	  the	  that	  of	  PDI,	  and	  fold	  increase	  of	  GPx8	  protein	  was	  calculated	  as	  above.	  Significance	  by	  
Student’s	  t	  statistic:	  P<0.001	  DES/BP	  vs.	  vehicle	  treated	  cells	  for	  both	  mRNA	  and	  protein	  analysis.	  
	  
Fig.	   4.	   The	   wild	   type	   hGPx8	   promoter	   activity	   increases	   by	   HIFα stabilization	   or	   individual	   HIFα subunits	  
transfection.	  Promoter	  activity	  was	  measured	  by	  reporter	  gene	  analysis.	  In	  A)	  HeLa	  cells	  were	  transfected	  with	  
the	   luciferase	   reporter	   construct	   pGL3GPx8wt	   containing	   1373	   nt	   upstream	   the	   transcriptional	   start	   of	   GPx8	  
encompassing	  the	  two	  putative	  HREs	  (Fig.	  1)	  or,	  for	  comparison,	  pGL3PGKHRE,	  containing	  six	  repetitions	  of	  PGK	  
HRE	   upstream	   the	   TK	   promoter	   [33].	   Cells	   were	   then	   treated	   with	   DES	   or	   BP	   for	   28	   hours,	   to	   stabilize	  
HIFα subunits,	  or	  vehicle	  as	  the	  control.	  In	  B)	  cells	  were	  transfected	  with	  the	  luciferase	  reporters	  as	  above,	  but	  
a	  construct	  expressing	  stable	  HIF1α	  or	  HIF2α	  was	  also	  co-­‐transfected	  and	  cells	  collected	  after	  48	  hr.	  Luciferase	  
activity	  was	  normalized	  for	  transfection	  efficiency	  as	  indicated	  in	  Methods	  and	  fold	  increase	  was	  calculated	  as	  
the	  ratio	  between	  sample	  and	  control.	  	  
	  
Fig.	  5.	  Mutation	  of	  each	  of	  the	  two	  GPx8-­‐HREs	  decreases	  promoter	  activity.	  Promoter	  activity	  was	  measured	  by	  
reporter	  gene	  analysis.	  HeLa	  cells	  were	  transfected	  with	  the	  wild	  type	  luciferase	  reporter	  containing	  the	  GPx8	  
promoter	   (pGL3GPx8wt)	   or	   the	  mutated	  ones	   carrying	  mutation	  at	   the	  GPx8-­‐HRE1	  or	  GPx8-­‐HRE2	   (pGL3GPx8mut1,	  
pGL3GPx8	  mut2	  respectively),	  pGL3GPx8	  mut1-­‐2	  carrying	  mutation	  at	  both	  sites,	  and	  treated	  with	  DES	  or	  BP.	  Controls	  
were	   treated	  with	   vehicle.	   The	  percentage	  of	   inhibition	  was	   calculated	   taking	   the	   fold	   increase	  of	   luciferase	  
activity	  of	  DES/BP-­‐treated	  cells	  transfected	  with	  the	  control	  plasmid	  (pGL3GPx8wt)	  as	  100%,	  thus	  the	  percentage	  
of	   inhibition	  of	   luciferase	  activity	   is	  0	   in	   these	   cells.	  Actual	   value	  +	  SD	   is	  5.06	  +	  0.63	  or	  3.96	  +	  0.9024	   in	   the	  
presence	  of	  DES	  or	  BP	   respectively.	   Significance	  by	  Student’s	   t	   statistic:	  P<	  0.05	  pGL3GPx8mut1	   vs.	  pGL3GPx8	  mut2	  
treated	  with	  DES;	  P<0.001	  pGL3GPx8mut1	  vs.	  pGL3GPx8	  mut2	  treated	  with	  BP.	  
 
Fig.	  6.	  Nuclear	  extracts	  containing	  stabilized	  HIFα subunits	  exhibits	  DNA	  binding	  activity	  when	  incubated	  with	  
GPx8-­‐HRE1	   or	   GPx8-­‐HRE2.	   Gel	   retardation	   assays	   were	   performed	   by	   biotin	   labeled	   double	   stranded	  
oligonucleotides	  (DSO)	  as	  indicated	  on	  top.	  Oligonucleotides	  were	  incubated	  with	  a	  nuclear	  extract	  from	  HeLa	  
cells	   previously	   treated	  with	  DES	   or	   BP	   (20	  mM	  or	   0.1	  mM	   respectively,	   for	   18	   hours)	   to	   stabilize	   the	  HIFα	  
subunits	  or	  vehicle	  as	  a	  control.	  Competition	  was	  performed	  with	  the	  indicated	  molar	  excess	  of	  the	  unlabeled	  
specific	  oligonucleotide	  that	  was	  added	  during	  the	  binding	  procedure,	  as	  a	  specificity	  control.	  Oligonucleotides	  
were	  as	   follows:	  A)	  GPx8-­‐HRE1,	  B)	  GPx8-­‐HRE2,	  C)	  EPO-­‐HRE.	  All	  of	   the	  oligonucleotides	  were	  of	  similar	   length	  
and,	  in	  D	  the	  binding	  of	  the	  indicated	  fragments	  to	  the	  nuclear	  extract	  is	  compared	  on	  the	  same	  gel.	  Lanes	  are	  
as	   follows:	   1,	   DSO;	   2,	   DSO,	   incubated	   with	   a	   nuclear	   extract	   from	   vehicle	   treated	   cells	   (control);	   3,	   DSO	  
incubated	   with	   a	   nuclear	   extract	   from	   DES-­‐treated	   cells;	   4,	   DSO	   incubated	   with	   a	   nuclear	   extract	   from	   BP-­‐
treated	   cells.	   5,6,7	   competition	   with	   unlabeled	   DSO	   at	   the	   indicated	   molar	   concentration;	   a,	   c,	   f,	   DSO,	  
incubated	   with	   a	   nuclear	   extract	   from	   vehicle	   treated	   cells	   (control);	   b,	   d,	   g	   DSO	   incubated	   with	   a	   nuclear	  
extract	  from	  DES-­‐treated	  cells;	  e,	  GPx8-­‐HRE2	  DSO.	  
	  
Fig.	   7.	   Silencing	   of	   the	   individual	   HIFα	   subunits	   indicate	   that	   HIF2α	   targets	   both	   the	  GPx8-­‐HREs.	   Promoter	  
activity	  was	  measured	   by	   reporter	   gene	   analysis.	   HeLa	   cells	  were	   transfected	  with	   the	   indicated	   siRNA	   and,	  
four	   hours	   later,	   with	   the	   reporter	   constructs	   pGL3GPx8wt,	   or	   pGL3GPx8mut1,	   or	   pGL3GPx8	  mut2	   and	   treated	   with	  
20mM	  DES	  or	  vehicle	   (control).	  Fold	   increase	  of	   luciferase	  activity	  was	  measured	  as	   in	  Fig.	  4.	   In	   the	   insert,	  a	  
proof	   of	   the	   efficacy	   of	   siRNA	   treatment	   is	   shown.	   HIFα	   subunits	   were	  measured	   by	   RTPCR	   as	   reported	   in	  
Methods	  using	   the	  oligonucleotides	   indicated	   in	  Table	  1.	  Significance	  by	  Student’s	   t	   statistic:	  P<	  0.001	  HIF2α	  
silenced	   cells	   transfected	   with	   pGL3GPx8wt	   or	   pGL3GPx8	  mut2	   vs.	   corresponding	   cells	   silenced	   with	   HIF1α	   or	  
scrambled	   nucleotides,	   and	   HIF2α	   silenced	   cells	   transfected	   with	   pGL3GPx8mut1	   vs.	   corresponding	   cells	  
transfected	   with	   scrambled	   nucleotides;	   P<	   0.1	   HIF2α	   silenced	   cells	   transfected	   with	   pGL3GPx8mut1	   vs.	  
corresponding	  cells	  silenced	  with	  HIF	  1	  alpha.	  
	  
Fig.	  8.	  hGPx8	  expression	  and	  promoter	  activity	  are	   increased	  by	  FGF	  treatment.	   In	  A)	  HeLa	  cells	  treated	  with	  
FGF	  (0.1µg/ml	  for	  10	  min)	  or	  vehicle	  (V)	  and	  GPx8	  mRNA	  analyzed	  and	  quantified	  as	  in	  Figure	  2.	  In	  B)	  HeLa	  cells	  
were	  transfected	  with	  pGL3PGKHRE	  or	  pGL3GPx8wt	  and	  treated	  with	  FGF	  or	  vehicle	  as	  described	  in	  Methods.	  Fold	  
increase	  of	  luciferase	  activity	  was	  measured	  as	  indicated	  in	  Figure	  3.	  	  
	  
Fig.	  9.	  GPx8	  silencing	  amplifies	  the	  signaling	  cascade	  induced	  by	  FGF	  or	  insulin.	  HeLa	  cells	  stably	  expressing	  a	  
siRNA	  targeted	  to	  GPx8	  or	  stably	  expressing	  shRNA	  (control	  cells)	  were	  treated	  with	  0.1	  µg/ml	  FGF	  or	  20	  µg/ml	  
insulin	  for	  10	  min.	  Untreated	  (U)	  cells	  were	  used	  as	  a	  control.	  Total	  cell	  lysates	  were	  probed	  (A)	  for	  P-­‐ERK1/2,	  
ERK	  by	  western	  blotting	  and	  quantified	  as	  described	  under	  Methods.	  (B)	  for	  P-­‐AKT	  and	  HSP90.	  Quantification	  
data	  are	  plotted	  on	  the	  right.	  The	  P-­‐ERK	  or	  P-­‐AKT	  signal	  relative	  to	  control	  cells	  was	  normalized	  to	  the	  ERK	  or	  




Tab.	  1.	  Synthetic	  oligonucleotides	  used	  in	  the	  study	  
 
PCR	  primers:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Sequence	  (5’-­‐>	  3’)	   note	  
HsGPx8-­‐fw	  	   TGCAGCTTACCCGCTAAAAT	   	  
HsGPx8-­‐rev	   ATGACTTCAATGGGCTCCTC	   	  
pGL3GPx8wt	  -­‐fw	   AATAGGTACCATTCATGACCGTTAGCAACA	   KpnI	  restriction	  site	  
bolfaced	  
pGL3GPx8wt-­‐rev	   ATTAAGATCTGAAGTCTCAGCAGCCTGGAATTCA	   BglII	  restriction	  sites	  
bolfaced	  
pGL3GPx8mut1-­‐fw	  	   ACGAAGCAATTAGATGATTAATCCAAGTAGAGGTGGGTTTTG	   GPx8-­‐HRE1	  boldfaced	  
pGL3GPx8mut1-­‐rev	  	  	   CAAAACCCACCTCTACTTGGATTAATCATCTAATTGCTTCGT	   GPx8-­‐HRE1	  boldfaced	  
pGL3GPx8mut2-­‐fw	   CAAAGTGCTGGGATTACAGTTAATAGCCACCATGCCCGGCCTCAG	   GPx8-­‐HRE2	  boldfaced	  
pGL3GPx8mut2-­‐rev	  	  	   CTGAGGCCGGGCATGGTGGCTATTAACTGTAATCCCAGCACTTTG	   GPx8-­‐HRE2	  boldfaced	  
HsHIF1α-­‐fw	  	   AGTTGAATCAGAAGATAC	   	  
HsHIF1α-­‐rev	   TGAGTCTGCTGGAATACT	   	  
HsHIF2α-­‐fw	   AAGCATCCCTGCCACCGT	   	  
HsHIF2α-­‐rev	   ATCAAAGGGCAGCTCCCA	   	  
HIFα 	  subunits	  
silencing:	  
	   	  
SiRNA-­‐HIF1α-­‐sense	   GCCACUUCGAAGUAGUGCUdTdT	   From	  ref.	  [33]	  
SiRNA-­‐HIF2α-­‐sense	  	   GCGACAGCUGGAGUAUGAAdTdT	   From	  ref.	  [33]	  
SiRNA-­‐scramble-­‐
sense	  
UAGCGACUAAACACAUCAAUUdTdT	   	  
EMSA	  analysis:	   	   	  
GPx8-­‐HRE1-­‐fw,	  	   GAAGCAATTAGATGACGTGCCCAAGTAGAG	   	  
GPx8-­‐HRE1-­‐rev	   CTCTACTTGGGCACGTCATCTAATTGCTTC	   	  
GPx8-­‐HRE2-­‐fw	   TGGGATTACAGGCGTGAGCCACCATGCCCG	   	  
GPx8-­‐HRE2-­‐rev	   CGGGCATGGTGGCTCACGCCTGTAATCCCA	   	  
EPO-­‐HREs-­‐fw	   ACGTGCTTACGTGCTTACGTGCTTACGTGC	   	  
EPO-­‐HREs-­‐rev	   GCACGTAAGCACGTAAGCACGTAAGCACGT	   	  
